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Abstract The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine 
resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. 
Combination therapy has been suggested as being an available and potentially lasting solution to this impending crisis. However, the 
current cost of combination therapy, and especially that of artemisinin combination therapy (ACT), is potentially a serious drawback, 
even if a signiﬁcant part of its cost is passed on to the end-user. If the question of cost is not successfully addressed this could lead 
to adverse results from the deployment of combination therapy as ﬁrst-line treatment. These adverse effects range from an increase 
in potentially fatal delays in infected individuals presenting to medical services, to exclusion of the poorest malaria sufferers from 
receiving treatment altogether. Urgent steps are needed to reduce the cost of combination therapy to the end-user in a sustainable 
way if it is to be usable, and some possible approaches are discussed.
Keywords Malaria, Falciparum/drug therapy; Antimalarials/economics; Drug therapy, Combination; Artemisinins/economics; Drug 
costs; Patient acceptance of health care; Financing, Organized; Africa (source: MeSH, NLM).
Mots clés Paludisme plasmodium falciparum/chimiothérapie; Antipaludique/économie; Polychimiothérapie; Artemisinines/économie; 
Coût médicament; Acceptation des soins; Organisation ﬁnancement; Afrique (source: MeSH, INSERM).
Palabras clave Paludismo falciparum/quimioterapia; Antimaláricos/economía; Quimioterapia combinada; Artemisininas/economía; 
Costos en drogas; Aceptación de la atención de salud; Organización (fuente: DeCS, BIREME).
Bulletin of the World Health Organization 2004;82:381-384.
Voir page 383 le résumé en français. En la página 384 ﬁgura un resumen en español.
1  Gates Malaria Partnership, London School of Hygiene and Tropical Medicine, 50 Bedford Square, London WC1B 3DP, England. Correspondence should be sent to  
 Christopher J.M. Whitty (email c.whitty@lshtm.ac.uk).
2  World Health Organization, 1211, Geneva 27, Switzerland. 
3  National Malaria Control Programme, Ministry of Health, Nairobi, Kenya. 
4  Department of Epidemiology, Ministry of Health, Kigali, Rwanda. 
5  National Malaria Control Programme, Ben Vonhm, Liberia. 
6  National Malaria Control Programme, Ministry of Health, Dar es Salaam, United Republic of Tanzania. 
7  Ministry of Health, Kinshasa, Democratic Republic of Congo. 
8  Department of Epidemiology and Preventive Medicine, Moi University, Eldoret, Kenya. 
9  Department of Parasitology, Muhimbili University College of Health Sciences, Dar es Salaam, United Republic of Tanzania. 
10 Medical Emergency Relief International (MERLIN), London, England.
11 East African Antimalarial Network (EANMAT), Muheza, United Republic of Tanzania. 
Ref. No. 03-006312
(Submitted: 14 July 03 – Final revised version received: 18 September 03 – Accepted: 23 September 03)
Averting a malaria disaster in Africa — where does the 
buck stop?
Christopher J.M. Whitty,1 Richard Allan,2 Virginia Wiseman,1 Sam Ochola,3 Maria Veronicah Nakyanzi-Mugisha,4 
Benjamin Vonhm,5 Mahemba Mwita,6 Constantin Miaka,7 Aggrey Oloo,8 Zul Premji,9 Craig Burgess,10  
& Theonest K. Mutabingwa11, 1
Policy and Practice
Drug-resistant malaria — the gathering storm
The serious threat posed by drug-resistant malaria in Africa is 
widely acknowledged (1). Chloroquine resistance is now uni-
versal, and the days of treating malaria with a single cheap drug 
are generally believed to be numbered. Resistance to sulfadoxine-
pyrimethamine (SP) the natural successor to chloroquine was 
increasing by the end of the 1990s. It was argued then that the 
only way to protect this or any other single drug is to give it in 
combination with another unrelated antimalarial as combina-
tion drug therapy (CDT) as in the case of tuberculosis (TB) 
treatment (1). Since the 1990s, the accelerating emergence and 
spread of resistance to SP has been documented in many areas, 
with parasitological failure rates of around 20% being widely 
reported, and up to 40–80% in certain areas (2, 3). Two rela-
tively cheap drugs could potentially replace SP as monotherapy; 
amodiaquine (an older drug with similarities to chloroquine) 
and chlorproguanil-dapsone (Lapdap, an anti-folate). Both are 
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currently effective in many areas where SP resistance already 
occurs, but this situation may well not last for much longer (2, 4). 
Resistance to amodiaquine already exists at an appreciable level in 
some areas (up to 26% in Kenya) (5). Because of its similarity to 
SP, there is a concern that resistance to chlorproguanil-dapsone 
may follow rapidly if it is deployed widely in areas of widespread 
SP resistance. We therefore face a crisis in treating malaria 
which is one of the most important causes of morbidity and 
mortality in Africa. The proposed CDT has received widespread 
scientiﬁc support and has the potential for returning Africa to 
sustainable, highly effective antimalarial treatment. The solu-
tion has, however, one serious drawback.
It has been suggested for some years that combinations 
of drugs, and especially combinations that include artemisinin 
drugs, will be highly effective in treating malaria. There is indirect 
evi-dence from south-east Asia (but not from Africa) that these 
combinations could also delay or halt the emergence of drug 
resistance. An informal expert consultation held by WHO in 2001 
supported the conclusion that combinations of drugs are the best, 
and possibly the only, long-term solution (6). Setting aside the 
question of cost, the consultation proposed a list of three arte-
misinin-containing combinations (lumefantrine–artemether, 
amodiaquine–artesunate and SP–artesunate) that they considered 
to have the greatest potential, and one non-artemisinin combi-
nation (SP–amodiaquine) was suggested as a fall-back option. 
Subsequent studies have conﬁrmed that these combinations are 
highly effective and safe (4, 5). A number of technical questions 
(for example on local effectiveness and safety in pregnancy) 
have yet to be answered and operational studies are required. 
One potential advantage of artemisinins, namely that they reduce 
transmission by reducing gametocyte carriage (7), has not been 
conﬁrmed in Africa and may not be relevant in areas with high 
transmission of malaria.
The principle that combination therapy could provide a 
rapid solution to a serious crisis and do so in a sustainable manner 
has, however, gained widespread support.
Cost — the major ﬂaw
There remains a serious problem with combination therapy, and 
that is its cost (1, 8, 9). Chloroquine and SP cost approximately 
US$ 0.15 for a course of treatment. Negotiation between the 
WHO and some drug companies has already successfully re-
duced the cost of combination treatment to between US$ 0.90 
and US$ 1.4 for a course of treatment for children up to seven 
years old and to approximately US$ 2 per adult dose. There are 
theoretical reasons for assuming that the cost might fall over 
time (10), but it seems unlikely to fall substantially below that 
negotiated by WHO in the immediate future, and making policy 
based on the assumption that cost may fall signiﬁcantly is rash.  
It is well established that combination therapies are more expen-
sive than current monotherapy and that the true opportunity 
cost of switching to combination therapy will signiﬁcantly exceed 
current drug price estimates. Therefore, issues of affordability 
can no longer be disregarded. The potential cost of combination 
therapy was viewed as “disastrous” in 1998 (11), a “major ob-
stacle” in 2000 (8), a “serious challenge” in 2001 (12), a “critical 
factor” in 2002 (9), and we still face a crisis in 2004.
In many parts of Africa a family member may have malaria 
several times per year, and febrile episodes treated as malaria more 
often still. A household may therefore have to pay for malaria 
treatment many times a year. If household income is only a few 
dollars a month, increasing the cost of malaria treatment with 
combination therapy even by US$ 0.5 will have grave conse-
quences, both direct and indirect.
At this cost, the poorest members of society will not be 
able to afford malaria treatment at all. Increasing user fees has 
been shown to have the potential to discriminate against the 
group in society whose health needs are greatest and who can 
therefore least afford to be deterred from seeking health care 
(13, 14). Malaria is particularly a disease of the poor and of 
populations affected by long-term conﬂict. One-third of the 
annual deaths from malaria worldwide occur in African countries 
affected by conﬂict (15). In one such area, up to 75% of the 
population were reported as being unable to afford even a full 
course of chloroquine from ofﬁcial health facilities or private 
markets (16). Consequently poorer parents already buy incom-
plete treatment or divide a full course of drugs between several 
family members. This results in treatment failure, increased selec-
tion pressure for drug resistance and increased prevalence of 
severe anaemia.
The problems of signiﬁcantly increased costs are not re-
stricted to people who cannot pay at all. Parents faced with high 
treatment costs commonly delay bringing their children or them-
selves for treatment until they are sure of the diagnosis. By this 
time the patient is often too sick to be treated successfully. It is 
the delay in receiving adequate treatment that kills many people 
with malaria. With prompt diagnosis and treatment with an efﬁca-
cious drug, most cases of malaria are entirely curable.
Other malaria sufferers will be put off going to formal 
medical services if the costs of drugs are too high and will seek 
their treatment from the informal sector where much antima-
larial treatment is already provided, often inappropriately (17). 
The effects of cost are not always predictable; in some instances 
ﬁnancial cost has had little effect on access to treatment or 
on adherence, but elsewhere it has played an important role 
in deterring people from attendance at antenatal clinics and 
hospitals (18).
Increased cost also has wider public health implications. 
The incentive to produce counterfeit drugs increases with the 
price at which they can be sold. Counterfeit antimalarials are 
only beginning to be a problem in Africa where low-cost drugs 
are used for ﬁrst-line treatment (19), but the problem is reaching 
serious proportions in south-east Asia where artemisinin-con-
taining combinations are in use (20).
Two conﬂicting, but correct positions
On the one hand there are drugs universally accepted to be 
close to ideal for the treatment of malaria. On the other hand, 
deploying these drugs as ﬁrst-line treatment if more than a 
fraction of the current cost is passed on to households, may 
prevent, delay or divert effective treatment-seeking behaviour. 
The public health impact of using these excellent drugs may 
even be worse than that of using a less effective but cheaper 
drug. Trying to pretend that there is no conﬂict is pointless 
— both positions are correct: combination therapy probably 
is the best solution, but deploying combination drugs at their 
current or foreseeable cost could be at best inequitable and at 
worst actively harmful.
The only way to reconcile these two positions is to provide 
combination therapy at a cost to households that is no greater 
than that of current malaria treatment, or better still, to provide 
treatment free of charge. This would render irrelevant all the 
current concerns about deploying combination therapy once 
the remaining technical issues have been addressed.
As there are only a few relatively well-deﬁned ways that 
this could be achieved, the technical questions to be answered 
are also relatively well deﬁned.
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Cost — some solutions will not work
We have already discussed the reasons why transferring the in-
creased cost burden to individuals will fail, regardless of whether 
the drugs were bought on the market or through a revolving 
drug fund or user fee. Published evaluations of user and drug-fee 
schemes suggest that they have been easier to impose than to 
enforce or sustain. The regressive nature of these fees continues 
to undermine the success of this type of health ﬁnancing policy 
(21, 22). Social insurance schemes would also be likely to fail, as 
those people most often affected by malaria are least often cov-
ered by insurance. In their review on rural risk-sharing schemes, 
Creese & Bennet (23) reported that schemes in low-income 
countries generally have only limited coverage, low cost-recovery 
rates and little ability to protect the most needy.
Individual governments in the affected countries, many of 
which are also coping with the twin epidemics of AIDS and TB, 
would rightly say that improvements in the medical and diagnostic 
infrastructure must take priority when allocating their limited 
resources. Malaria remains a severe economic burden on most of 
these countries, reducing GDP by up to 18% (24), and, therefore, 
dealing with it effectively should be an economic as well as a 
humanitarian priority. Diagnostic facilities for malaria do already 
exist, although as with TB and HIV services, the diagnostic services 
for malaria in many areas need to be strengthened signiﬁcantly 
as a matter of priority, especially if more expensive drugs are to 
be used. In areas with low endemicity of malaria such improve-
ments may include considering the use of new malaria dipsticks, 
although these have severe technical limitations in areas of high 
endemicity. Improving diagnostic infrastructure is necessary 
irrespective of which drugs are used, although with more expen- 
sive drugs, improved rational use of drugs increases their cost-
effectiveness.
However, the burden of subsidizing the drug costs is almost 
certainly unrealistically high for the governments of countries 
with a high endemicity of malaria to bear. Put in perspective, the 
entire health care budget of a country such as Rwanda is around 
US$ 10 million. According to recent estimates, this might just 
cover the cost of changing malaria treatment (10). Malaria is a 
problem that is not going to disappear with investment, so loans 
are not appropriate. In the many countries of Africa affected 
by long-term conﬂicts, bank loans and bilateral grants are not 
even an option. This limits the available choices. Although some 
of the countries in which malaria is endemic may be able to 
contribute signiﬁcantly towards the solution to the growing 
malaria treatment crisis with both material and management 
resources, most cannot meet the costs of more expensive drugs 
without assistance.
Subsidy — the only realistic option
Support from pharmaceutical companies and donors has an 
important role to play, but if combination therapy for malaria 
is to be deployed, the international donor community would 
have to make a major and indeﬁnite commitment to buying or 
subsidizing the drugs so that the cost to the end-user is low or 
non-existent. This could mean subsidizing indigenous produc-
tion, subsidizing the drugs before they arrive in countries in 
which malaria is endemic, or supporting low-cost production. 
Subsidy up to the point that the costs of combination therapy are 
equivalent to the costs of the currently used drugs is one option, 
but the provision of free drugs has many additional advantages. 
Ironically drug treatment for malaria is free in almost all middle-
income and high-income countries — but not in the poorest. 
Strong political support will also be essential at country level to 
ensure that low-cost or free malaria treatment provided at the 
centre remains so to health providers and malaria patients.
The provision of free drugs would be a bold step, but not 
without precedent. Several excellent TB and leprosy control 
programmes have worked on the basis of free (donated) drug 
programmes. Such a programme would be achievable over a 
short period of time as the basic infrastructure already exists 
and the drugs are licensed. Few of the operational problems 
that have been highlighted for antiretroviral treatment for 
HIV/AIDS in Africa (25) would occur with malaria because 
treatment courses are relatively short, and there is no need for 
follow-up and monitoring. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria potentially provides a mechanism that 
could be used to fund malaria drugs sustainably, without relying 
on a single donor (26).
Conclusion
Combination drug therapy offers a safe and effective potential 
solution to the spread of drug-resistant malaria which is one of 
the great public health crises looming over Africa. Unless the real 
cost considerations of combination drug therapy are met, this 
urgently needed new therapeutic approach can never achieve 
its full potential. Attempting to deploy combination therapy as 
ﬁrst-line treatment without addressing this problem could para-
doxically make things worse for the poorest and most vulnerable 
malaria sufferers. The solution is, ultimately, a political rather 
than a scientiﬁc one. This is not an issue that can be ignored, 
and the speed of onset of the crisis means that ﬁnding a solu-
tion cannot be delayed.  O
Conﬂicts of interest: none declared.
Résumé
Eviter une catastrophe liée au paludisme en Afrique : quel compromis ?
La grave menace que constitue la propagation du paludisme 
pharmacorésistant en Afrique est largement reconnue. La 
résistance à la chloroquine est maintenant presque générale et 
la résistance à la sulfadoxine-pyriméthamine, le successeur de la 
chloroquine, gagne rapidement du terrain. On a émis l’idée que 
la polychimiothérapie pouvait représenter une solution accessible 
et peut-être durable à cette crise imminente. Cependant, le coût 
actuel d’un tel traitement, en particulier lorsqu’il comporte une 
artémisinine, risque d’être un inconvénient majeur, même s’il est 
supporté pour une grande partie par le patient lui-même. Si l’on 
ne résout pas la question du coût du traitement, l’adoption de 
la polychimiothérapie comme traitement de première intention 
risque d’avoir des conséquences fâcheuses, allant du décès de 
malades qui auront attendu trop longtemps avant de faire appel 
aux services médicaux, à l’exclusion des malades les plus pauvres 
de tout traitement. Il est urgent de prendre des mesures pour 
réduire durablement le coût de la polychimiothérapie pour le 
patient si l’on veut qu’elle soit applicable ; certaines orientations 
sont proposées.
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Resumen
Malaria en África: delimitar las responsabilidades para evitar una catástrofe
La grave amenaza planteada por la propagación de la malaria 
farmacorresistente en África es un problema ampliamente 
reconocido. La resistencia a la cloroquina es ya casi universal, y la 
resistencia al medicamento sucesor, la sulfadoxina-pirimetamina 
(SP), está extendiéndose rápidamente.  Se ha sugerido el recurso a 
la politerapia como solución disponible y potencialmente duradera 
para esta crisis inminente.  Sin embargo, el actual costo de la 
politerapia, especialmente el de las combinaciones basadas en la 
artemisinina (PA), constituye un posible inconveniente grave, aun 
cuando una parte signiﬁcativa de ese costo se traslade al usuario. 
Si no se aborda satisfactoriamente ese problema, el despliegue 
de la politerapia como tratamiento de primera línea podría 
conducir a resultados adversos, desde un aumento de los retrasos 
potencialmente mortales en la búsqueda de atención médica por 
los individuos infectados, hasta la exclusión total del tratamiento 
de los enfermos de malaria más pobres.  Se requieren medidas 
urgentes a ﬁn de reducir el costo de la politerapia para el usuario 
de manera sostenible y hacer así viable esa opción, y se examinan 
aquí algunas de las posibles estrategias en esa línea.
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